Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of maridebart cafraglutide in adults with overweight or obesity, with or without type 2 diabetes mellitus
jRCT2031220664Phase 2Completed
- Sponsor
- Amgen
- Start
- Jan 2023
- Modality
- Peptide-Protein Conjugates → Peptide Conjugates → Peptides, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Modified Peptides → Peptides
01
Overview
Phase 2, randomised, double-blind trial of maridebart cafraglutide in obesity, Overweight and type 2 diabetes mellitus (T2DM), sponsored by Amgen. Primary endpoint: Percent change from baseline to Week 52 in body weight. Started Jan 2023; status: completed.
02
Drugs
maridebart cafraglutide
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2031220664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220664.